News & Updates
Filter by Specialty:

Which factors improve survival in ICI-treated patients with NSCLC?
The survival benefit derived from using immune checkpoint inhibitors (ICIs) is more evident in patients with advanced nonsmall cell lung cancer (NSCLC) who received first-line therapy, showed low neutrophil/lymphocyte ratio (NLR), and had no history of hormone use following initial treatment, suggests a recent study.
Which factors improve survival in ICI-treated patients with NSCLC?
25 Apr 2023
Patients at risk for BE worried over EAC but rarely undergoes screening: study
Patients who are prone to Barrett’s esophagus (BE), specifically those belonging to racial and ethnic minorities, express concern about developing esophageal adenocarcinoma (EAC), reveals a study. However, they seldom go through screening and lack awareness of screening recommendations.
Patients at risk for BE worried over EAC but rarely undergoes screening: study
25 Apr 2023
HK doctors’ mental HRQoL significantly worse than the general population
Doctors in Hong Kong have significantly poorer mental health-related quality of life (HRQoL) than the general population, with high rates of depression and burnout, a survey has shown.
HK doctors’ mental HRQoL significantly worse than the general population
25 Apr 2023
Psilocybin shows therapeutic potential for depression
For cancer patients with depression, treatment with a single dose of psilocybin appears to yield rapid and meaningful improvements in depressive symptoms, as shown in a phase II study.
Psilocybin shows therapeutic potential for depression
24 Apr 2023
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
Mirvetuximab soravtansine (MIRV), an antibody drug conjugate (ADC), showed antitumour activity in women with platinum-resistant ovarian cancer* (PROC) with high folate receptor alpha (FRα) expression, findings from the phase III SORAYA study have shown.